Innovus Pharmaceuticals Inc (INNV) 0.1520 $INNV Innovus

New Post Public Reply Private Reply Replies (0) Message Board

May 17, 2015 at 9:44 AM

Innovus Pharmaceuticals Inc (INNV) 0.1520 $INNV

Innovus Pharmaceuticals Announces the Official Launch of Sensum+(R) in Morocco by its Partner Ovation Pharma with an Initial Order of Approximately 240,000 Doses
ACCESSWIRE - Tue May 12, 8:48AM CDT
SAN DIEGO, CA / ACCESSWIRE / May 12, 2015 / Innovus Pharmaceuticals, Inc., ("Innovus Pharma" or the "Company) www.innovuspharma.com (OTCQB: INNV) a company focusing on the commercialization of over-the-counter ("OTC"

and consumer products for men's and women's health, vitality and respiratory diseases announced today that its partner Ovation Pharma officially launched Sensum+(R) in Morocco. The launch took place during the annual meeting of the Moroccan Association of Urology in Rabat from May 07 to May 09. Ovation Pharma launched the product with an initial order of approximately 240,000 doses. Sensum+(R) is currently promoted by Ovation Pharma sales force and will be placed behind the counter and dispensed with a physician prescription.

SeeThruEquity Issues Update on Innovus Pharmaceuticals and Maintains Target Price of $1.34
ACCESSWIRE - Mon Apr 27, 8:01AM CDT
NEW YORK, NY / ACCESSWIRE / April 27, 2015 / SeeThruEquity, a leading New York City based independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has issued an update on Innovus Pharmaceuticals, Inc. (OTCQB: INNV).

Innovus Pharmaceuticals Announces Receipt of Marketing Authorization for Zestra? in the United Arab Emirates
ACCESSWIRE - Thu Apr 16, 12:44PM CDT
SAN DIEGO, CA / ACCESSWIRE / April 16, 2015 / Innovus Pharmaceuticals, Inc., ("Innovus Pharma" or the "Company) www.innovuspharma.com (OTCQB: INNV) a company focusing on the commercialization of over-the-counter ("OTC"

and consumer products for men's and women's health, vitality and respiratory diseases announced today that its partner Sothema Laboratories, ("Sothema"

received marketing authorization for Zestra(R) in the United Arab Emirates (the "UAE"

.

Innovus Pharma Signs Exclusive Marketing and Distribution Agreement with Oz Biogenics to Market and Distribute Zestra(R) EjectDelay(R) Sensum+(R) Vesele(R) and Zestra Glide(R) in Myanmar and Vietnam
ACCESSWIRE - Mon Apr 13, 5:16AM CDT
SAN DIEGO, CA / ACCESSWIRE / April 13, 2015 / Innovus Pharmaceuticals, Inc., ("Innovus Pharma"

www.innovuspharma.com (OTCQB:INNV) announced today it has entered into an exclusive marketing and distribution agreement with Oz Biogenics based in Australia ("Oz Biogenics"

under which Innovus Pharma has granted to Oz Biogenics an exclusive ten-year license and distribution rights to market and sell Innovus Pharma's products including Zestra(R) to increase Female Sexual Arousal and Desire and Satisfaction, EjectDelay(R) for treating premature ejaculation, Sensum+(R) to increase penile sensitivity, Vesele(R) for sexual functions and cognitive responses and Zestra Glide(R) the high viscosity water based lubricant. Oz Biogenics is in the process of negotiating commercial agreements with pharmaceutical companies in those countries to promote the product in the medical and mainstream channels. The annual minimum orders are approximately eight hundred sixty five thousand dollars over the ten year term of the agreement.

Innovus Pharma Signs Exclusive License and Distribution Agreement with BroadMed for Sensum+(R) in Lebanon
ACCESSWIRE - Wed Apr 08, 6:16PM CDT
Innovus Eligible to Receive up to $11.1 Million in Upfront and Sales; Milestone Payments plus Double-Digit Tiered Royalties

Innovus Pharmaceuticals 2014 Revenues Increase to over $1Million in Its First Full Year of Commercial Operations
ACCESSWIRE - Wed Apr 01, 6:15PM CDT
Company Signs Approximately $2 Million in Minimum Annual Orders from Its Seven Commercial Partners for Its Products

Innovus Pharma Signs Exclusive License and Distribution Agreement with Tabuk Pharmaceuticals for EjectDelay(R), Sensum+(R) and Vesele(R) in Saudi Arabia, the Gulf Countries, North Africa and the Middle East
ACCESSWIRE - Mon Mar 23, 10:47AM CDT
Innovus Eligible to Receive up to $86.5 Million in Upfront and Sales Milestone Payments plus Royalties

Innovus Pharma inks exclusive deal in Middle East
Seeking Alpha - at Seeking Alpha - Mon Mar 23, 7:23AM CDT

Innovus Pharmaceuticals unveils Zestra and Zestra Glide for FSI/AD in Morocco
M2 - Tue Feb 17, 3:21AM CST
OTC health company Innovus Pharmaceuticals (Other OTC:INNV) reported on Monday the official launch of Zestra and Zestra Glide for treating Female Sexual Desire Disorder (FSI/AD) in pharmacies in Morocco.

Innovus Pharmaceuticals Announces the Official Launch of Zestra(R) and Zestra Glide(R) in Morocco by its Partner Sothema Labs with an Initial Order Approximately 200,000 Doses
ACCESSWIRE - Mon Feb 16, 5:00AM CST
SAN DIEGO, CA / ACCESSWIRE / February 16, 2015 / Innovus Pharmaceuticals, Inc., ("Innovus Pharma" or the "Company"

www.innovuspharma.com (OTCQB: INNV) a company focusing on the commercialization of over-the-counter ("OTC"

and consumer products for men's and women's health, vitality and respiratory diseases announced today that its partner Sothema Laboratories, ("Sothema Labs"

officially launched Zestra(R) and Zestra Glide(R) in Morocco. The launch press conference took place at the Hyatt Regency Hotel in Casablanca and was attended by Dr. Bassam Damaj, the President and CEO of the Innovus Pharma along with the executives of Sothema Labs. Sothema Labs launched the products with an initial order of approximately 200,000 doses. Innovus Pharma delivered half of the order and is expected to ship the remainder before the end of this quarter. Zestra(R) is currently promoted by Sothema Laboratories with a large sales force, and is available in pharmacies in Morocco, placed behind the counter and dispensed with a physician prescription.

Innovus Pharma merges with Novalere FP, nabs rights to steroid nasal spray
Seeking Alpha - at Seeking Alpha - Thu Feb 05, 10:44AM CST

Innovus Pharma Enters $1 Billion Worldwide Nasal Steroid Market with the Acquisition of FlutiCare(TM) (Fluticasone Propionate Nasal) Over The Counter ("OTC"

Rights from Novalere
ACCESSWIRE - Thu Feb 05, 10:40AM CST
- Transformative acquisition establishes Innovus's position as a leading respiratory OTC Pharmaceutical Company

Innovus Pharmaceuticals to Present at the 17th Annual BIO CEO & Investor Conference in New York
ACCESSWIRE - Tue Feb 03, 5:00AM CST
SAN DIEGO, CA / ACCESSWIRE / February 3, 2015 / Innovus Pharmaceuticals, Inc. ("Innovus Pharma"

, www.innovuspharma.com, (OTCQB: INNV) an emerging commercial stage pharmaceutical company that delivers safe, innovative and effective non-prescription over-the counter medicine and consumer care products to improve men and women's health and vitality and treat respiratory diseases today announced that Dr. Bassam Damaj, Ph.D., President and Chief Executive Officer, will present at the 17th Annual BIO CEO & Investor Conference, to be held at the Waldorf-Astoria Hotel in New York February 9-10, 2015. Dr. Damaj is scheduled to present on Monday, February 9th at 8 a.m. EST.

Innovus Pharma Expands its Men's Health Franchise with the Addition of Exclusive Rights to Androferti(R) to Support Overall Male
ACCESSWIRE - Wed Jan 28, 8:02AM CST
Innovus Pharma Expands its Men's Health Franchise with the Addition of Exclusive Rights to Androferti(R) to Support Overall Male Reproductive Health and Sperm Quality for the U.S. and Canadian Market

Innovus Pharmaceuticals to Present at OneMedForum in San Francisco
ACCESSWIRE - Tue Jan 06, 12:00PM CST
SAN DIEGO, CA / ACCESSWIRE / January 6, 2015 / Innovus Pharmaceuticals, Inc. ("Innovus Pharma"

, (OTCQB: INNV), an emerging commercial stage pharmaceutical company that delivers safe, innovative and effective non-prescription over-the counter medicine and consumer care products to improve men and women's health and vitality, announced today that it will be presenting at the OneMedForum held in San Francisco, CA from January 12 - 13, 2015 at the San Francisco Marriot Marquis.

Innovus Pharma Management Discusses the Company's Revenue Stream and Growth Strategy with TheStockRadio.com
ACCESSWIRE - Thu Dec 18, 7:14AM CST
Innovus Pharma Management Discusses the Company's Revenue Stream and Growth Strategy with TheStockRadio.com

Innovus Pharma Expands Agreement with Tramorgan Limited to Commercialize Vesele(R) in the United Kingdom
ACCESSWIRE - Thu Dec 11, 9:54AM CST
Innovus Eligible to Receive up to $13 Million in Sales Milestone Payments plus 50% Royalties on Sales of Vesele(R)

Innovus Pharmaceuticals to Present at LD Micro Conference in Los Angeles on December 2, 2014
ACCESSWIRE - Wed Nov 26, 5:00AM CST
San Diego, CA / ACCESSWIRE / November 26, 2014 / Innovus Pharmaceuticals, Inc. ("Innovus Pharma"

www.innovuspharma.com (OTCQB: INNV) a company focusing on the commercialization of over-the-counter ("OTC"

and consumer products for men's and women's health and vitality announced today a positive analysis and outcome of a 246 use survey study in the United Kingdom for Zestra(R) in women, conducted by Semprae Laboratories prior to its acquisition by Innovus Pharma, but never reported. In this use survey study, 246 women, including a large number of nurse practitioners between the ages of 30-60 years old, used Zestra(R) over a period of two weeks. Users were asked to answer a modified diary of the FSFI score.

Innovus Pharmaceuticals Provides Third Quarter 2014 Financial Results With Commercial and Corporate Update
ACCESSWIRE - Fri Nov 14, 11:30AM CST
Revenues Up by 289% to $443,087 for Third Quarter 2014 Compared to Second Quarter 2014

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Skiptown Expands in Georgia Amid Growing Demand

With the pet care industry barking up a storm lately, Skiptown is ramping up efforts to expand its presence in Georgia. The tech-enabled dog care franchise already has a paw print in Atlanta, but it's sniffing out new opportunities across the state. Now they're on the hunt for franchise owners who can bring this modern approach to more communities. Why Georgia? The Growth...

AtWork Welcomes Franchise Vet Sarah Goehring

A Strategic Move for AtWork There's a new heavyweight at AtWork, a name that's been catching attention in the franchise biz lately—Sarah Goehring. This isn't just another appointment; it's a signal flare for AtWork's ambitions. With Goehring, they're doubling down on scaling their operation and drawing in more franchise players who are ready to hit the ground running....

Omneky Outshines Competitors in AI Ad Scoring

Brewing a better ad with AI isn't just about the model you plug in—it's about the wizardry wrapping around it. Omneky's latest caper in the AI advertising game has snagged the spotlight, pulling a hearty 8.8 taste score on a recent TasteBench comparison. That's not a minor tweak, folks, but a whopping 1.2-point lead over the shadow-chasing curves of the next...

OmniActive's Fenavari: A New Era in Women's Health

Pioneering Women's Health with Fenavari You ever wonder why some health products get all the hype? Here's one for the book: OmniActive Health Technologies launching Fenavari, their top-tier contender in the women's health market. Now, we're not talking your run-of-the-mill supplement here. We're stepping onto a new playing field, especially with Dr. Taz Bhatia stepping...

Veterans Transitioning to Real Estate with Scholarships

Tapping Military Skills for Civilian Gain Finding a new career after military service is a mountain of a task, but veterans now have a golden ticket into the real estate appraisal world. The Appraisal Institute's Next Mission Scholarship is throwing veterans a $1,000 life preserver to dive into a field where their military-honed skills already shine. The Power of a...

Think Tank Pushes for Bold Parkinson's Prevention Plan

A New Era for Parkinson's Disease Prevention The Parkinson's Foundation has rolled out its battle plan to take on Parkinson's disease from the ground up, shifting gears from managing symptoms to stopping the illness before it starts. It's about damn time, too. With the disease being the fastest-growing neurodegenerative disorder and impacting 10 million people worldwide,...

VetsinTech's AI Training Boosts Military Careers

A New Spin on Engineering Careers Sometimes it feels like every corner I turn in this market maze, there’s something about AI. It’s not just chirping in the tech world anymore; it’s banging on the doors of sectors like engineering, aerospace, and manufacturing. And now, VetsinTech is tossing its hat into the AI ring with a fresh program aimed at blending military...

Montessori and Tech: A New Era of Integration

Reimagining Montessori with Technology Let's take a stroll down the road less traveled—the intersection of Montessori education and tech. For over a century, Montessori schools have valued individual child development, autonomy, and a purpose-driven environment. But let's face it, their technology hasn't always had the same handcrafted finesse. That's where illumine...

Fluence Energy Faces Major Lawsuit Amid $3B Loss

Securities Class Action: A Storm Brewing Just when you think you've got a grip on the market, a sharp right hook can come out of nowhere. Fluence Energy (NASDAQ:FLNC) is dealing with one of those punches now, getting dragged into the courtroom over claims they fudged financial lines. They hail innovation in energy storage, but shareholders are left shaking in their boots...

Coventry's Jacobs Joins European Life Settlement Execs

Neal Jacobs Steps Up in Life Settlements Coventry has added another feather to its cap with Neal Jacobs, their Senior Managing Director of Capital Markets, joining the Executive Committee of the European Life Settlement Association (ELSA). Elected at ELSA's Annual General Meeting on September 15, 2026, Jacobs brings a wealth of experience that promises to bolster the...